Characteristics of the 427 patients
| . | No. . |
|---|---|
| Male:female | 255:172 |
| Median age, y (range) | 31 (0-66) |
| Underlying disease, no. (%) | |
| Lymphoma, multiple myeloma | 196 (46) |
| Acute leukemia, myelodysplasia, PNH | 136 (32) |
| Myeloproliferative disease | 56 (13) |
| Other | 39 (9) |
| Advanced underlying disease,* no. (%) | 315/415 (76) |
| Type of HSC transplantation, no. (%) | |
| Autologous/syngeneic | 181 (42) |
| Allogeneic, myeloablative | 208 (49) |
| Allogeneic, nonmyeloablative | 38 (9) |
| Type of donor and HLA status, no. (%) | |
| HLA-compatible sibling | 187/246 (76) |
| HLA-compatible unrelated | 28/246 (11) |
| HLA-mismatched unrelated | 33/246 (13) |
| Conditioning regimen, no. (%) | |
| Busulfan based | 119 (28) |
| TBI based | 85 (20) |
| Other | 223 (52) |
| Stem cell source, no. (%) | |
| Peripheral blood | 225 (53) |
| Bone marrow | 168 (39) |
| Cord blood | 34 (8) |
| . | No. . |
|---|---|
| Male:female | 255:172 |
| Median age, y (range) | 31 (0-66) |
| Underlying disease, no. (%) | |
| Lymphoma, multiple myeloma | 196 (46) |
| Acute leukemia, myelodysplasia, PNH | 136 (32) |
| Myeloproliferative disease | 56 (13) |
| Other | 39 (9) |
| Advanced underlying disease,* no. (%) | 315/415 (76) |
| Type of HSC transplantation, no. (%) | |
| Autologous/syngeneic | 181 (42) |
| Allogeneic, myeloablative | 208 (49) |
| Allogeneic, nonmyeloablative | 38 (9) |
| Type of donor and HLA status, no. (%) | |
| HLA-compatible sibling | 187/246 (76) |
| HLA-compatible unrelated | 28/246 (11) |
| HLA-mismatched unrelated | 33/246 (13) |
| Conditioning regimen, no. (%) | |
| Busulfan based | 119 (28) |
| TBI based | 85 (20) |
| Other | 223 (52) |
| Stem cell source, no. (%) | |
| Peripheral blood | 225 (53) |
| Bone marrow | 168 (39) |
| Cord blood | 34 (8) |
PNH indicates paroxysmal nocturnal hemoglobinuria; HSC, hematopoietic stem cell; HLA, human leukocyte antigen; and TBI, total body irradiation.
Not applicable to hereditary disorders such as Fanconi anemia and Wiskott-Aldrich syndrome.